SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What happens when you give Claude Code a blank webpage, and full control?

The Best Website Ever

BWE is trending amidst bearish sentiment, with traders actively shorting and anticipating further drops. The community expresses concerns about potential market manipulation and broader economic anxieties such as inflation, tariffs, and a possible recession impacting crypto.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community anticipates a potential breakout, fueled by discussions around key price levels and historical patterns. Some traders suggest it's primed for a significant move, while others remain skeptical, pointing to past underperformance relative to Bitcoin and other altcoins. The conversation also touches on Litecoin's utility, privacy features, and potential for wider adoption.

Monero

Monero (XMR) is trending as the conversation revolves around its use case as a privacy coin and potential breakout. Community members are discussing Monero's stability and expressing excitement over its potential, with some drawing comparisons to other privacy coins like ZEC. The broader discussion includes Monero's role in a future where privacy is highly valued, particularly with the rise of CBDCs and increasing government regulation.

Concordium is the Layer-1 blockchain built for a new era of digital trust. With mandatory, privacy-preserving identity verification built into its consensus layer, utilizing zero-knowledge proof technology. Concordium also enables Protocol-level tokens that eliminate smart contract risks by being issued directly at the consensus layer, with built-in features that provide the infrastructure for compliance-ready use cases. At its core is Smart Money - programmable, identity-embedded, and compliance-ready value that powers trusted interactions across Web3. Smart Money enables frictionless exchange, automation, and verifiable trust by design. Unlike conventional blockchains, Concordium integrates trust, accountability, and privacy into its architecture from the ground up  bridging traditional systems and Web3 to build a transparent, sustainable digital future. The name Concordium comes from the Latin concordia—meaning harmony and agreement—a reflection of its mission to build infrastructure that embeds trust, privacy, and compliance into every interaction.

Concordium

Concordium ($CCD) is trending as the community highlights its focus on privacy, compliance, and real-world utility, particularly in the PayFi space. The recent partnership with bitcoin.com/ is seen as a significant catalyst, driving discussions around its potential as a leading infrastructure play for stablecoins and regulated DeFi. Some believe $CCD is undervalued, emphasizing its unique approach to balancing privacy and transparency.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

KPTI is trending due to significant community frustration directed at the company's CEO and board, with accusations of mismanagement and value destruction. This sentiment is further fueled by concerns regarding recent financial transactions and the company's cash runway. Some analysts maintain a positive outlook, while others express doubt about the leadership's ability to navigate KPTI towards success.

SSgA Active Trust - Consumer Discretionary Select Sector SPDR

Consumer Discretionary Select Sector SPDR Fund

Consumer Discretionary Select Sector SPDR Fund ($XLY) is trending due to positive earnings reports from companies like Airbnb and Amazon, suggesting strong consumer demand. The community is also discussing the potential impact of tariffs on retail and holiday spending. Some analysts are pointing to technical indicators, like price strength and momentum, to support further gains in the sector.

BtcUSD is a completely decentralized stablecoin issued and managed by BTCFi, a platform where users can deposit Bitcoin of various formats to use as collaterals. BtcUSD offers Bitcoin holders the opportunity to generate additional yields with their Bitcoin positions through DeFi usage.

Bitcoin USD (BTCFi)

Bitcoin is trending as the community debates its short-term bearish signals versus long-term bullish potential, with some eyeing key support levels and others anticipating a parabolic move towards new highs. Discussions range from Elliott Wave analysis suggesting further downside to predictions of a major rise based on historical patterns and increasing institutional ownership. Bullish sentiment revolves around Bitcoin's fixed supply and anticipation of increased demand, with some projecting targets well above previous all-time highs.

Sei is a high-performance Layer 1 blockchain that scales the EVM with parallelized execution, enabling faster transactions, low fees, and seamless smart contract deployment. Sei removes traditional blockchain bottlenecks while maintaining full Ethereum compatibility. The upcoming Giga upgrade will deliver 50x improvements in EVM throughput, optimizing execution, consensus, and storage to push blockchain performance to web2 levels.

SEI is trending as the community discusses its potential, comparing it to other Layer-1 blockchains like SUI and Solana, with some suggesting it could make a similar surge. Recent news and developments, including integrations and partnerships, are driving optimism, though some traders express concerns about price action relative to the positive news. Technical analysis and price predictions are also circulating, as well as the proposal of an ETF.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR Protocol is currently trending amidst discussions about its user growth and potential within the AI sector. Community members are weighing in on entry points and breakout setups, while some highlight NEAR's rise in active users compared to other blockchains. There's also buzz around staking opportunities and upcoming events related to NEAR's ecosystem.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is trending as the community focuses on its potential within the Base ecosystem and its integration with Coinbase. Discussions revolve around the strong fundamentals of the token, anticipating further price appreciation as more users get onboarded and altseason approaches. Some users are pointing to a competitor, HYDX, as a reason for the recent price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4D Molecular Therapeutics (NASDAQ:FDMT) Raised to Equal Weight at Morgan Stanley

Morgan Stanley upgraded shares of 4D Molecular Therapeutics from an "underweight" rating to an "equal weight" rating in a report on Friday...

<ul class="summary-bullets"><li>4D-150 demonstrated consistent and durable benefits in patients with wet age-related macular degeneration in the study.&nbsp;</li><li>The company is currently enrolling patients into late-stage trials for the drug.</li><li>Enrollment is continuing ahead of initial projections, CEO David Kirn said. &nbsp;</li></ul>4D Molecular Therapeutics (FDMT) announced on Thursday that its experimental drug 4D-150 demonstrated consistent and durable benefits in patients with wet age-related macular degeneration in an early-to-mid-stage trial.Wet age-related macular degeneration (AMD) is an advanced form of macular degeneration where abnormal blood vessels grow in the retina, leak fluid or blood, and cause a rapid decline in central vision. The proliferation and leakage of abnormal blood vessels is stimulated by vascular endothelial growth factor (VEGF), a protein that promotes the growth of new blood vessels. According to 4D, the disease has a high incidence, with 200,000 individuals estimated to be newly diagnosed every year in the U.S. alone.<h2 class="st-heading-2">Study Findings</h2>4D-150 showed maintenance of visual acuity and control of retinal anatomy in the study, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-announces-positive-long-term-data-phase-12-prism-clinical">said</a>. The study also reduced treatment burden as patients maintained a consistent and clinically meaningful reduction in supplemental injections in 6-month intervals following dosing with 4D-150 through up to two years of follow-up, it added.4D-150 was further well tolerated with no new safety or intraocular inflammation findings. The drug is aimed at providing multi-year, and potentially lifelong, sustained delivery of anti-VEGF from the retina with a single, safe, intravitreal injection. Anti-VEGF is a treatment that blocks the action of the vascular endothelial growth factor.The company is currently enrolling patients into late-stage trials for the drug. Enrollment is continuing ahead of initial projections, according to CEO David Kirn.“With the robust PRISM dataset and our APAC region strategic partnership with Otsuka announced last week, we are well positioned for global success in our Phase 3 4FRONT clinical trials, which continue to enroll ahead of initial projections,” he added. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company soared 13% in the pre-market session at the time of writing. On Stocktwits, retail sentiment regarding <a href="https://stocktwits.com/symbol/FDMT">FDMT stock</a> remained within the ‘bullish’ territory, while message volume remained at ‘high’ levels over the past 24 hours.FDMT stock is up 89% this year and approximately 26% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dupont-announces-2-billion-share-buyback-stock-tumble-7-today/cL2t8hLREbz">DuPont Announces $2 Billion Share Buyback: Why Did The Stock Tumble 7% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

FDMT Stock Gains Pre-Market After Positive Study Data For Experimental Drug In Eye Disease

The drug showed maintenance of visual acuity, control of retinal anatomy, and reduction of treatment burden at all time points with up to 2 years of follow-up. 

Equity

The drug showed maintenance of visual acuity, control of retinal anatomy, and reduction of treatment burden at all time points with up to 2 years of follow-up. 


Wall Street Analysts See a 208.52% Upside in 4D Molecular Therapeutics (FDMT): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 208.5% in 4D Molecular Therapeutics (FDMT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag

Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -11.36% and -98.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of...

Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm

Kaskela Law LLC announces that it is investigating 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) (4D Molecular) on behalf of the companys stockholders. Since March 2024, shares of 4D Moleculars...

FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. (4D Molecular Therapeutics or...

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

4D Molecular Therapeutics Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Current Price	$10.50
Prev Close	$10.92
Open	$11.02
Dividend Yield	0.00%
50-Day Moving Average	$8.91
Beta	1.31
Avg. Volume	873,657.91
PE Ratio	-2.83

52-Week High	$12.34
52-Week Low	$2.24
Market Capitalization	$490.38M
EPS (Annual)	-$2.98
Price to Book	1.17
Revenue Per Employee	$163.00
Enterprise Value/EBITDA	N/A

FDMT
4D Molecular Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FDMT News

FDMT4D Molecular Therapeutics Inc